Purpose To determine the safety of high dose/long duration (HD/LD) Amphotericin B Lipid Complex (ABLC) treatment of fungal infections in comparison to low dose/short duration (LD/SD) ABLC therapy. Methods A large multi center patient registry, the Collaborative Exchange of Antifungal Research (CLEAR) was used to retrospectively review patients treated with HD/LD (>5mg/kg/d for >12d, median dose of 5.6 mg/kg/d, range of 5 10 mg/kg/d for a median duration of 21 days, range of 13 - 182 days) and LD/SD (5mg/kg/d for >12 days does not appear to compromise patient renal function even in patients who receive concomitant nephrotoxic medication(s).
Full conference title:
14th Annual Focus on Fungal Infections
- FFI 14th (2004)